Welcome to our dedicated page for Azitra news (Ticker: AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.
Azitra Inc (AZTR) is a clinical-stage biopharmaceutical leader advancing precision dermatology through engineered microbial therapies. This page serves as the definitive source for verified updates on the company's scientific progress and corporate developments.
Investors and industry observers will find timely information on clinical trial milestones, regulatory filings, and research collaborations. Our curated news collection covers essential updates including therapeutic pipeline advancements, intellectual property developments, and strategic partnership announcements.
All content undergoes rigorous verification to ensure accuracy and relevance. The news archive maintains focus on material developments in Azitra's core areas: live biotherapeutic products, genetic engineering innovations, and dermatological treatment solutions. Regular updates provide insight into the company's progress addressing conditions like Netherton syndrome and EGFR inhibitor-associated rashes.
Bookmark this page for efficient tracking of Azitra's advancements in microbial therapeutics and precision dermatology research. For comprehensive understanding of the company's scientific approach, review our detailed company profile alongside these verified updates.
Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company, announced positive preclinical data for ATR-04, aimed at treating EGFR inhibitor-induced dermal toxicity. This condition affects about 150,000 patients in the US. The data, presented at the Society of Investigative Dermatology 2024 Annual Meeting, showed ATR-04 reducing methicillin-resistant S. aureus (MRSA) by 99% in ex vivo pig skin and reducing the pro-inflammatory cytokine IL-36γ by 75% in treated human skin models. Additionally, ATR-04 increased human beta defensin 18-fold compared to the vehicle in human skin models. These results support an upcoming IND application to the FDA for a Phase 1b trial in patients undergoing EGFR inhibitors with dermal toxicity.
Azitra, Inc. announces positive preclinical data of ATR-12 and clinical design in Netherton Syndrome presented at the ASGCT Annual Meeting. ATR-12 inhibits key protease driving Netherton syndrome, delivers LEKTI more effectively than topical application, reduces pro-inflammatory cytokine IL-36g, is safe in minipigs, and shows promising results for a Phase 1b study. The study aims to evaluate safety, efficacy, and skin pharmacokinetics of ATR-12 in Netherton syndrome patients.
Azitra, Inc. (NYSE American: AZTR) reported financial results for Q1 2024, showcasing advancement in clinical trials and pre-IND meetings. The company strengthened its IP portfolio, completed a public offering, and progressed in partnership discussions. With a focus on dermatology treatments, Azitra aims to revolutionize severe skin condition treatments, delivering value to shareholders. Financially, the company saw an increase in R&D and G&A expenses, with a net loss of $2.9 million for Q1 2024.
FAQ
What is the current stock price of Azitra (AZTR)?
What is the market cap of Azitra (AZTR)?
